CDIO Overview

Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.

PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.

Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.

Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.

Partnership Announcement: Cardio Diagnostics is partnering with the YMCA of East Tennessee to offer a customized program for its members, which includes educational sessions called "Wisdom Wednesdays" and discounted access to AI-powered cardiovascular tests.

Heart Disease Statistics: Heart disease is the leading cause of death in the U.S., with Tennessee having a notably high cardiovascular mortality rate, highlighting the importance of early detection and prevention initiatives.

Educational Initiatives: The program will feature six educational sessions starting in November 2025, focusing on coronary heart disease prevention and proactive heart health management.

Community Access: The collaboration aims to extend cardiovascular testing and educational resources beyond YMCA members to the entire East Tennessee community, promoting heart health awareness and proactive measures.

Expansion of Partnerships: Cardio Diagnostics has partnered with 15 new provider organizations across the U.S., showcasing the growing adoption of their AI-driven precision cardiovascular medicine tests, Epi+Gen CHD™ and PrecisionCHD™.

Diverse Care Models: The new partnerships span various medical specialties and care models, including concierge, functional medicine, and primary care practices, emphasizing personalized and preventive healthcare approaches.

Innovative Testing Technology: The integration of Epi+Gen CHD™ and PrecisionCHD™ allows providers to gain actionable insights into coronary heart disease and heart attack risk, enhancing patient care and treatment plans.

Mission for Accessibility: Cardio Diagnostics aims to make precision cardiovascular medicine more accessible, addressing the rising prevalence of cardiovascular disease and improving early detection and management across diverse patient populations.